Altimmune’s (ALT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Altimmune (NASDAQ:ALT) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

ALT has been the topic of a number of other research reports. UBS Group began coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.83.

Altimmune Stock Down 1.1 %

Altimmune stock opened at $6.98 on Wednesday. The firm has a fifty day moving average of $7.88 and a 200-day moving average of $7.20. Altimmune has a 52-week low of $5.28 and a 52-week high of $14.84. The firm has a market capitalization of $496.42 million, a P/E ratio of -4.50 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period last year, the company posted ($0.39) earnings per share. On average, research analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Institutional investors have recently modified their holdings of the stock. Bellevue Group AG raised its position in shares of Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Altimmune in the 3rd quarter worth about $674,000. Barclays PLC boosted its holdings in shares of Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after buying an additional 4,772 shares during the last quarter. Finally, Stifel Financial Corp raised its stake in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after acquiring an additional 7,746 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.